20-quarter listed-company comparison

Medical Distribution Stocks

Medical Distribution: McKesson Corporation owns the largest revenue base; Cardinal Health, Inc. has the fastest current growth.

01 · the industry itself · before any single company

How has Medical Distribution moved against S&P 500?

The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the most recent two of them this industry is 27% ahead of S&P 500. Earnings across its companies grew 23% on average over the last four reported quarters. It has been ahead of S&P 500 on a rolling three-month view for 4 weeks running.

TURNING · ahead 4w~Price and the fundamentals both up5 of 7 companies ahead of S&P 500 by 5% or more over three months

RS ↑4w · 4/7 >200d (+0) · 5/7 lead (+3) · EPS 4/7↑

Medical Distribution, equal-weighted, based at 200 S&P 500, same base, same start trailing 12-month earnings per share rising falling

Both lines start at 200 in the same week, so the distance between them is the whole story: the industry line is an equal-weighted index of its 7 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member rebased to 100 at the start and the industry taking the median — so a price line pulling away from flat bars is a re-rating, not earnings. A bar turns red when that figure is lower than the quarter before. Rules are fixed and applied identically everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover any point to read both values and the gap. This is a description of what the numbers did, not advice.

02 · sector relative strength, before individual stocks

Is Medical Distribution outperforming S&P 500?

Medical Distribution has outperformed S&P 500 by 32.8% over the last 52 weeks. Over 13 weeks the gap is a lead of 6.5%. 3 of 7 covered companies currently beat the S&P 500 on Mansfield relative strength, so leadership inside the sector is selective. EDAP TMS S.A. is the strongest against the sector itself at +53.4%.

+6.5%Sector vs S&P 500 · 13 weeks

+32.8%Sector vs S&P 500 · 52 weeks

3/7Stocks leading S&P 500

2/7Stocks leading sector

Sector metric: — as of latest available · unclassified · direction unavailable.

The central tension: the companies with the most scale are not necessarily the companies creating the most change.

Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.

Bottom line

Medical Distribution has outperformed S&P 500 by 32.8% over 52 weeks and 6.5% over 13 weeks. 3 of 7 covered companies beat the S&P 500 on Mansfield relative strength, while 2 of 7 beat the sector itself. McKesson Corporation leads with revenue of $403,430 million, based on 6 of 8 comparable companies through Mar 2026.

Companies

complete canonical membership

Combined market value

$223.3B

McKesson Corporation

Revenue growing

5/6

positive TTM year-on-year growth

Beating S&P 500

3/7

positive Mansfield relative strength

Comparing 5 of 8

03 · research priority, made explicit

4-Factor Sector Score

An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.

Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%

McKesson Corporation has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 85.3% evidence confidence.

Cardinal Health, Inc. looks inexpensive relative to peers or its own history, but its earnings trajectory has not yet earned the valuation signal.

Cardinal Health, Inc. has stronger price confirmation than earnings confirmation; that is a research prompt, not permission to chase.

How this score is built, and what the marks mean

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

Company	Score	Price stage	Growth & earnings/35	Capital efficiency/25	Valuation/20	Relative strength/20
1McKesson CorporationMCK	71.4/100Favorable setup85% evidence	TURNING	28.7/35 Revenue 12.4% · PAT 46.5% · OPM change 0.4 pp 95% evidence	16.2/25 ROCE 14.9% · OPM 2.2% 76% evidence	15.9/20 P/E 22.5× · PEG 0.46 65% evidence	10.6/20 RS sector -14% · RS bench -8.6% · 1Y 24.2%1 of 12 weeks ahead 100% evidence
Exact sum: 28.7 + 16.2 + 15.9 + 10.6 = 71.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
2Cencora, Inc.COR	56.0/100Mixed-positive evidence85% evidence	TURNING	19.6/35 Revenue 6% · PAT 49.6% · OPM change 0.1 pp 95% evidence	12.1/25 ROCE 5.3% · OPM 1.5% 76% evidence	15.3/20 P/E 24.1× · PEG 0.47 65% evidence	9.0/20 RS sector -19.7% · RS bench -14.4% · 1Y 7.4%1 of 12 weeks ahead 100% evidence
Exact sum: 19.6 + 12.1 + 15.3 + 9 = 56 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3Cardinal Health, Inc.CAH	48.0/100Mixed-negative evidence85% evidence	TURNING	9.9/35 Revenue 12.8% · PAT -0.7% · OPM change -0.5 pp 95% evidence	9.8/25 ROCE 3.6% · OPM 0.8% 76% evidence	13.1/20 P/E 32.3× · PEG 1.01 65% evidence	15.2/20 RS sector -0.7% · RS bench 5.1% · 1Y 48.4%3 of 12 weeks ahead 100% evidence
Exact sum: 9.9 + 9.8 + 13.1 + 15.2 = 48 · Decision use: Price leads the evidence: RS versus the benchmark is 5.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
4Henry Schein, Inc.HSIC	46.7/100Mixed-negative evidence85% evidence	BREAKING OUT	11.4/35 Revenue 5.6% · PAT 1% · OPM change -0.1 pp 95% evidence	11.9/25 ROCE 2.3% · OPM 5.4% 76% evidence	6.5/20 P/E 21.8× · PEG 3.23 65% evidence	16.9/20 RS sector 0.1% · RS bench 6.4% · 1Y 35.1%4 of 12 weeks ahead 100% evidence
Exact sum: 11.4 + 11.9 + 6.5 + 16.9 = 46.7 · Decision use: Price leads the evidence: RS versus the benchmark is 6.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
5EDAP TMS S.A.FOCL	43.5/100Mixed-negative evidence61% evidence	BREAKING OUT	15.0/35 Revenue 11.9% · PAT — · OPM change 2.8 pp 71% evidence	3.0/25 ROCE -18.6% · OPM -41.4% 76% evidence	8.5/20 P/E 75× · PEG — 15% evidence	17.0/20 RS sector 53.4% · RS bench 60.3% · 1Y 407.2%9 of 12 weeks ahead 70% evidence
Exact sum: 15 + 3 + 8.5 + 17 = 43.5 · Decision use: Price leads the evidence: RS versus the benchmark is 60.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
6Accendra Health, Inc.ACH	32.4/100Adverse evidence61% evidence	ASLEEP	12.0/35 Revenue 0% · PAT — · OPM change -0.2 pp 71% evidence	7.8/25 ROCE 0.8% · OPM 2.7% 76% evidence	9.1/20 P/E 67.3× · PEG — 15% evidence	3.5/20 RS sector -27.4% · RS bench -21.1% · 1Y -58.5%6 of 12 weeks ahead 70% evidence
Exact sum: 12 + 7.8 + 9.1 + 3.5 = 32.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
7Empro Group Inc.EMPG	56.1/100Thin evidence · provisional18% evidence		18.8/35 Revenue — · PAT — · OPM change 65.6 pp 10% evidence	17.3/25 ROCE 39.6% · OPM 36.1% 57% evidence	10.0/20 P/E — · PEG — 0% evidence	10.0/20 RS sector — · RS bench — · 1Y 212.2%2 of 2 weeks ahead to 2025-10-10 0% evidence
Exact sum: 18.8 + 17.3 + 10 + 10 = 56.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
8Akso Health GroupAHG	37.8/100Thin evidence · provisional34% evidence	BASING	17.5/35 Revenue — · PAT — · OPM change — 12% evidence	6.3/25 ROCE -0.7% · OPM — 61% evidence	10.0/20 P/E — · PEG — 0% evidence	4.0/20 RS sector -27.4% · RS bench -22.8% · 1Y -16.4%1 of 12 weeks ahead 70% evidence
Exact sum: 17.5 + 6.3 + 10 + 4 = 37.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

04 · what price has already done

Market action

EDAP TMS S.A. has the strongest one-year price move in Medical Distribution at +407.2%. It also leads on Mansfield relative strength against the S&P 500 at +60.3%. 3 of 7 covered companies are above zero on that measure. Every line covers 314 weekly closes through 2026-08-04.

Price and relative strength

Every company, the sector's own index and S&P 500 all start level on the left edge of the window, so only the distance between the lines counts — the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.

05 · compare level, then change

Revenue Scale & Growth Durability

McKesson Corporation has the highest Revenue among the 8 Medical Distribution companies compared here, at $403,430 million. Cencora, Inc. is next at $328,681 million. Cardinal Health, Inc. has the highest Revenue growth at 12.8%, so level and change sit with different companies. 6 of 8 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: McKesson Corporation is the scale leader at $403,430 million, 22.7% ahead of Cencora, Inc.. Cardinal Health, Inc.'s growth is 12.8% from a $250,735 million base, with 20 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.

LeaderMcKesson Corporation · $403,430 million

Gap22.7% versus #2 · Cencora, Inc.

Persistence8/8 recent comparable periods

Coverage6/8 companies · 132 observations

Investor read: McKesson Corporation is the scale benchmark; Cardinal Health, Inc. is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.

This conclusion weakens if: McKesson Corporation's growth falls below Cardinal Health, Inc.'s for two consecutive comparable reports while operating margin also compresses.

Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.

Revenuelargest

1McKesson Corporation MCK$403.4B

2Cencora, Inc. COR$328.7B

3Cardinal Health, Inc. CAH$250.7B

4Henry Schein, Inc. HSIC$13.4B

5Accendra Health, Inc. ACH$2.7B

Revenue growthfastest growers

1Cardinal Health, Inc. CAH13%

2McKesson Corporation MCK12%

3EDAP TMS S.A. FOCL12%

4Cencora, Inc. COR6.0%

5Henry Schein, Inc. HSIC5.6%

Revenue · company comparison

6/8 level · 6/8 change

On every company-comparison chart on this page: solid lines show level, dotted lines show change when “Both” is selected, and a missing report breaks the line rather than being invented.

All-company data · latest reported quarter

In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

Company	Revenue	Revenue growth	Reported
McKesson Corporation MCK	$96.3B	6.0%	Mar 2026
Cencora, Inc. COR	$78.4B	3.9%	Mar 2026
Cardinal Health, Inc. CAH	$60.9B	11%	Mar 2026
Henry Schein, Inc. HSIC	$3.4B	6.3%	Mar 2026
Accendra Health, Inc. ACH	$628M	-6.8%	Mar 2026
EDAP TMS S.A. FOCL	$18M	29%	Mar 2026
Akso Health Group AHG	$7M	0.0%	Mar 2026
Empro Group Inc. EMPG	$4M	100%	Dec 2024

Full 20-quarter history · every available company

Revenue · reported quarter history

Accendra Health, Inc. · ACH

Jun 2021$2.5B

Sep 2021$2.5B

Dec 2021$2.5B

Mar 2022$2.4B

Jun 2022$2.5B

Sep 2022$2.5B

Dec 2022$2.6B

Mar 2023$2.5B

Jun 2023$2.6B

Sep 2023$2.6B

Dec 2023$2.7B

Mar 2024$2.6B

Jun 2024$660M

Sep 2024$687M

Dec 2024$695M

Mar 2025$674M

Jun 2025$682M

Sep 2025$697M

Dec 2025$709M

Mar 2026$628M

Akso Health Group · AHG

Jun 2021—

Sep 2021$0M

Dec 2021—

Mar 2022$6M

Jun 2022—

Sep 2022$12M

Dec 2022—

Mar 2023$1M

Jun 2023—

Sep 2023$1M

Dec 2023—

Mar 2024$2M

Jun 2024—

Sep 2024$7M

Dec 2024—

Mar 2025$8M

Jun 2025—

Sep 2025$7M

Dec 2025—

Mar 2026—

Cardinal Health, Inc. · CAH

Jun 2021$42.6B

Sep 2021$44.0B

Dec 2021$45.5B

Mar 2022$44.8B

Jun 2022$47.1B

Sep 2022$49.6B

Dec 2022$51.5B

Mar 2023$50.5B

Jun 2023$53.4B

Sep 2023$54.7B

Dec 2023$57.4B

Mar 2024$54.9B

Jun 2024$59.9B

Sep 2024$52.3B

Dec 2024$55.3B

Mar 2025$54.9B

Jun 2025$60.2B

Sep 2025$64.0B

Dec 2025$65.6B

Mar 2026$60.9B

Cencora, Inc. · COR

Jun 2021$53.4B

Sep 2021$58.9B

Dec 2021$59.6B

Mar 2022$57.7B

Jun 2022$60.1B

Sep 2022$61.2B

Dec 2022$62.8B

Mar 2023$63.5B

Jun 2023$66.9B

Sep 2023$68.9B

Dec 2023$72.3B

Mar 2024$68.4B

Jun 2024$74.2B

Sep 2024$79.1B

Dec 2024$81.5B

Mar 2025$75.5B

Jun 2025$80.7B

Sep 2025$83.7B

Dec 2025$85.9B

Mar 2026$78.4B

EDAP TMS S.A. · FOCL

Jun 2021$12M

Sep 2021$11M

Dec 2021$16M

Mar 2022$14M

Jun 2022$15M

Sep 2022$12M

Dec 2022$17M

Mar 2023$16M

Jun 2023$16M

Sep 2023$12M

Dec 2023$22M

Mar 2024$16M

Jun 2024$17M

Sep 2024$15M

Dec 2024$21M

Mar 2025$14M

Jun 2025$19M

Sep 2025$16M

Dec 2025$22M

Mar 2026$18M

Empro Group Inc. · EMPG

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023$2M

Sep 2023—

Dec 2023$2M

Mar 2024—

Jun 2024$2M

Sep 2024—

Dec 2024$4M

Mar 2025—

Jun 2025—

Sep 2025—

Dec 2025—

Mar 2026—

Henry Schein, Inc. · HSIC

Jun 2021$3.0B

Sep 2021$3.2B

Dec 2021$3.3B

Mar 2022$3.2B

Jun 2022$3.0B

Sep 2022$3.1B

Dec 2022$3.4B

Mar 2023—

Jun 2023$3.1B

Sep 2023$3.1B

Dec 2023$3.0B

Mar 2024$3.2B

Jun 2024$3.1B

Sep 2024$3.2B

Dec 2024$3.2B

Mar 2025$3.2B

Jun 2025$3.2B

Sep 2025$3.3B

Dec 2025$3.4B

Mar 2026$3.4B

McKesson Corporation · MCK

Jun 2021$62.7B

Sep 2021$66.6B

Dec 2021$68.6B

Mar 2022$66.1B

Jun 2022$67.2B

Sep 2022$70.2B

Dec 2022$70.5B

Mar 2023$68.9B

Jun 2023$74.5B

Sep 2023$77.2B

Dec 2023$80.9B

Mar 2024$76.4B

Jun 2024$79.3B

Sep 2024$93.7B

Dec 2024$95.3B

Mar 2025$90.8B

Jun 2025$97.8B

Sep 2025$103.2B

Dec 2025$106.2B

Mar 2026$96.3B

Revenue growth · reported quarter history

Accendra Health, Inc. · ACH

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 20220.4%

Sep 2022-0.2%

Dec 20223.4%

Mar 20234.8%

Jun 20232.5%

Sep 20233.8%

Dec 20234.1%

Mar 20243.6%

Jun 2024-74%

Sep 2024-74%

Dec 2024-74%

Mar 2025-74%

Jun 20253.3%

Sep 20251.5%

Dec 20252.0%

Mar 2026-6.8%

Akso Health Group · AHG

Jun 2021—

Sep 2021-100%

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023-83%

Jun 2023—

Sep 2023-92%

Dec 2023—

Mar 2024100%

Jun 2024—

Sep 2024600%

Dec 2024—

Mar 2025300%

Jun 2025—

Sep 20250.0%

Dec 2025—

Mar 2026—

Cardinal Health, Inc. · CAH

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 202211%

Sep 202213%

Dec 202213%

Mar 202313%

Jun 202314%

Sep 202310%

Dec 202312%

Mar 20248.7%

Jun 202412%

Sep 2024-4.3%

Dec 2024-3.8%

Mar 20250.0%

Jun 20250.5%

Sep 202522%

Dec 202519%

Mar 202611%

Cencora, Inc. · COR

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 202212%

Sep 20223.8%

Dec 20225.4%

Mar 20239.9%

Jun 202311%

Sep 202313%

Dec 202315%

Mar 20247.8%

Jun 202411%

Sep 202415%

Dec 202413%

Mar 202510%

Jun 20258.7%

Sep 20255.9%

Dec 20255.5%

Mar 20263.9%

EDAP TMS S.A. · FOCL

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 202225%

Sep 20229.1%

Dec 20226.3%

Mar 202314%

Jun 20236.7%

Sep 20230.0%

Dec 202329%

Mar 20240.0%

Jun 20246.3%

Sep 202425%

Dec 2024-4.6%

Mar 2025-13%

Jun 202512%

Sep 20256.7%

Dec 20254.8%

Mar 202629%

Empro Group Inc. · EMPG

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 20240.0%

Sep 2024—

Dec 2024100%

Mar 2025—

Jun 2025—

Sep 2025—

Dec 2025—

Mar 2026—

Henry Schein, Inc. · HSIC

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 20222.1%

Sep 2022-3.5%

Dec 20221.2%

Mar 2023—

Jun 20231.0%

Sep 20231.1%

Dec 2023-11%

Mar 2024—

Jun 20242.5%

Sep 20242.4%

Dec 20245.8%

Mar 2025-0.1%

Jun 20253.3%

Sep 20255.2%

Dec 20257.7%

Mar 20266.3%

McKesson Corporation · MCK

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 20227.2%

Sep 20225.4%

Dec 20222.7%

Mar 20234.3%

Jun 202311%

Sep 202310%

Dec 202315%

Mar 202411%

Jun 20246.4%

Sep 202421%

Dec 202418%

Mar 202519%

Jun 202523%

Sep 202510%

Dec 202511%

Mar 20266.0%

06 · compare level, then change

Operating Economics & Margin Trend

Empro Group Inc. has the highest OPM among the 8 Medical Distribution companies compared here, at 36.1%. Henry Schein, Inc. is next at 5.4%. The same company also holds the highest Margin change, at +65.6 percentage points. 7 of 8 companies report a comparable reading, the latest through Dec 2024.

What the numbers say: Empro Group Inc. leads both opm at 36.1% and margin change at +65.6 percentage points.

LeaderEmpro Group Inc. · 36.1%

Gap568.5% versus #2 · Henry Schein, Inc.

Persistence1/2 recent comparable periods

Coverage7/8 companies · 123 observations

Investor read: Empro Group Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.

OPMhighest

1Empro Group Inc. EMPG · older report36%

2Henry Schein, Inc. HSIC5.4%

3Accendra Health, Inc. ACH2.7%

4McKesson Corporation MCK2.2%

5Cencora, Inc. COR1.5%

Margin changefastest expanders

1Empro Group Inc. EMPG · older report+65.6 pp

2EDAP TMS S.A. FOCL+2.8 pp

3McKesson Corporation MCK+0.4 pp

4Cencora, Inc. COR+0.1 pp

5Henry Schein, Inc. HSIC−0.1 pp

Operating margin · company comparison

7/8 level · 7/8 change

All-company data · latest reported quarter

Company	OPM	Margin change	Reported
Empro Group Inc. EMPG	36%	+65.6 pp	Dec 2024
Henry Schein, Inc. HSIC	5.4%	−0.1 pp	Mar 2026
Accendra Health, Inc. ACH	2.7%	−0.2 pp	Mar 2026
McKesson Corporation MCK	2.2%	+0.4 pp	Mar 2026
Cencora, Inc. COR	1.5%	+0.1 pp	Mar 2026
Cardinal Health, Inc. CAH	0.8%	−0.5 pp	Mar 2026
EDAP TMS S.A. FOCL	-41%	+2.8 pp	Mar 2026

Full 20-quarter history · every available company

OPM · reported quarter history

Accendra Health, Inc. · ACH

Jun 20213.9%

Sep 20212.5%

Dec 20212.5%

Mar 20222.5%

Jun 20223.0%

Sep 20222.4%

Dec 2022-2.1%

Mar 20230.4%

Jun 20230.4%

Sep 20230.9%

Dec 20232.3%

Mar 20240.4%

Jun 20242.6%

Sep 20244.5%

Dec 2024-39%

Mar 20252.9%

Jun 2025-5.8%

Sep 20253.8%

Dec 20252.9%

Mar 20262.7%

Cardinal Health, Inc. · CAH

Jun 20210.4%

Sep 20210.9%

Dec 2021-2.1%

Mar 2022-0.2%

Jun 20220.1%

Sep 20220.3%

Dec 2022-0.2%

Mar 20231.1%

Jun 20230.3%

Sep 2023-0.1%

Dec 20230.9%

Mar 20240.7%

Jun 20240.7%

Sep 20241.1%

Dec 20241.0%

Mar 20251.3%

Jun 20250.7%

Sep 20251.0%

Dec 20251.1%

Mar 20260.8%

Cencora, Inc. · COR

Jun 20211.2%

Sep 20211.0%

Dec 20211.1%

Mar 20221.4%

Jun 20220.8%

Sep 20220.7%

Dec 20221.0%

Mar 20230.9%

Jun 20231.0%

Sep 20230.7%

Dec 20231.1%

Mar 20240.8%

Jun 20240.9%

Sep 20240.2%

Dec 20240.9%

Mar 20251.4%

Jun 20251.1%

Sep 20250.0%

Dec 20250.9%

Mar 20261.5%

EDAP TMS S.A. · FOCL

Jun 2021-4.1%

Sep 2021-20%

Dec 20213.3%

Mar 2022-0.8%

Jun 2022-3.0%

Sep 2022-18%

Dec 2022-10%

Mar 2023-44%

Jun 2023-30%

Sep 2023-47%

Dec 2023-18%

Mar 2024-32%

Jun 2024-39%

Sep 2024-45%

Dec 2024-18%

Mar 2025-44%

Jun 2025-36%

Sep 2025-36%

Dec 2025-27%

Mar 2026-41%

Empro Group Inc. · EMPG

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 20239.0%

Sep 2023—

Dec 2023-30%

Mar 2024—

Jun 2024-16%

Sep 2024—

Dec 202436%

Mar 2025—

Jun 2025—

Sep 2025—

Dec 2025—

Mar 2026—

Henry Schein, Inc. · HSIC

Jun 20217.1%

Sep 20216.6%

Dec 20216.0%

Mar 20227.7%

Jun 20227.3%

Sep 20226.9%

Dec 20222.1%

Mar 2023—

Jun 20235.7%

Sep 20236.5%

Dec 20231.3%

Mar 20244.7%

Jun 20245.1%

Sep 20244.9%

Dec 20244.9%

Mar 20255.5%

Jun 20254.7%

Sep 20254.9%

Dec 20254.7%

Mar 20265.4%

McKesson Corporation · MCK

Jun 20210.9%

Sep 20210.8%

Dec 20210.4%

Mar 20221.0%

Jun 20221.5%

Sep 20221.6%

Dec 20221.8%

Mar 20231.4%

Jun 20231.5%

Sep 20231.2%

Dec 20230.8%

Mar 20241.6%

Jun 20241.3%

Sep 20240.6%

Dec 20241.3%

Mar 20251.8%

Jun 20251.1%

Sep 20251.4%

Dec 20251.5%

Mar 20262.2%

Margin change · reported quarter history

Accendra Health, Inc. · ACH

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022−0.9 pp

Sep 2022−0.1 pp

Dec 2022−4.6 pp

Mar 2023−2.1 pp

Jun 2023−2.6 pp

Sep 2023−1.5 pp

Dec 2023+4.4 pp

Mar 20240.0 pp

Jun 2024+2.2 pp

Sep 2024+3.6 pp

Dec 2024−41.5 pp

Mar 2025+2.5 pp

Jun 2025−8.4 pp

Sep 2025−0.7 pp

Dec 2025+42.1 pp

Mar 2026−0.2 pp

Cardinal Health, Inc. · CAH

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022−0.3 pp

Sep 2022−0.6 pp

Dec 2022+1.9 pp

Mar 2023+1.3 pp

Jun 2023+0.2 pp

Sep 2023−0.4 pp

Dec 2023+1.1 pp

Mar 2024−0.4 pp

Jun 2024+0.4 pp

Sep 2024+1.2 pp

Dec 2024+0.1 pp

Mar 2025+0.6 pp

Jun 20250.0 pp

Sep 2025−0.1 pp

Dec 2025+0.1 pp

Mar 2026−0.5 pp

Cencora, Inc. · COR

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022−0.4 pp

Sep 2022−0.3 pp

Dec 2022−0.1 pp

Mar 2023−0.5 pp

Jun 2023+0.2 pp

Sep 20230.0 pp

Dec 2023+0.1 pp

Mar 2024−0.1 pp

Jun 2024−0.1 pp

Sep 2024−0.5 pp

Dec 2024−0.2 pp

Mar 2025+0.6 pp

Jun 2025+0.2 pp

Sep 2025−0.2 pp

Dec 20250.0 pp

Mar 2026+0.1 pp

EDAP TMS S.A. · FOCL

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022+1.1 pp

Sep 2022+2.5 pp

Dec 2022−13.3 pp

Mar 2023−43.5 pp

Jun 2023−26.6 pp

Sep 2023−29.8 pp

Dec 2023−7.7 pp

Mar 2024+12.0 pp

Jun 2024−9.3 pp

Sep 2024+2.8 pp

Dec 2024−0.7 pp

Mar 2025−11.9 pp

Jun 2025+2.9 pp

Sep 2025+9.0 pp

Dec 2025−8.9 pp

Mar 2026+2.8 pp

Empro Group Inc. · EMPG

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024−24.9 pp

Sep 2024—

Dec 2024+65.6 pp

Mar 2025—

Jun 2025—

Sep 2025—

Dec 2025—

Mar 2026—

Henry Schein, Inc. · HSIC

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022+0.2 pp

Sep 2022+0.3 pp

Dec 2022−3.9 pp

Mar 2023—

Jun 2023−1.6 pp

Sep 2023−0.4 pp

Dec 2023−0.8 pp

Mar 2024—

Jun 2024−0.6 pp

Sep 2024−1.6 pp

Dec 2024+3.6 pp

Mar 2025+0.8 pp

Jun 2025−0.4 pp

Sep 20250.0 pp

Dec 2025−0.2 pp

Mar 2026−0.1 pp

McKesson Corporation · MCK

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022+0.6 pp

Sep 2022+0.8 pp

Dec 2022+1.4 pp

Mar 2023+0.4 pp

Jun 20230.0 pp

Sep 2023−0.4 pp

Dec 2023−1.0 pp

Mar 2024+0.2 pp

Jun 2024−0.2 pp

Sep 2024−0.6 pp

Dec 2024+0.5 pp

Mar 2025+0.2 pp

Jun 2025−0.2 pp

Sep 2025+0.8 pp

Dec 2025+0.2 pp

Mar 2026+0.4 pp

07 · compare level, then change

Profit Scale & Acceleration

McKesson Corporation has the highest Net profit among the 8 Medical Distribution companies compared here, at $5,099 million. Cencora, Inc. is next at $2,553 million. Cencora, Inc. has the highest Profit growth at 49.6%, so level and change sit with different companies. 6 of 8 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: McKesson Corporation leads with $5,099 million of TTM profit, 99.7% above Cencora, Inc.. Cencora, Inc. shows 49.6% growth from a $2,553 million profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.

LeaderMcKesson Corporation · $5,099 million

Gap99.7% versus #2 · Cencora, Inc.

Persistence5/8 recent comparable periods

Coverage6/8 companies · 132 observations

Investor read: McKesson Corporation sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.

Net profitlargest

1McKesson Corporation MCK$5.1B

2Cencora, Inc. COR$2.6B

3Cardinal Health, Inc. CAH$1.5B

4Henry Schein, Inc. HSIC$418M

5EDAP TMS S.A. FOCL$-32M

Profit growthfastest growers

1Cencora, Inc. COR50%

2McKesson Corporation MCK47%

3Henry Schein, Inc. HSIC1.0%

4Cardinal Health, Inc. CAH-0.7%

Net profit · company comparison

6/8 level · 4/8 change

All-company data · latest reported quarter

Company	Net profit	Profit growth	Reported
McKesson Corporation MCK	$1.9B	42%	Mar 2026
Cencora, Inc. COR	$1.6B	127%	Mar 2026
Cardinal Health, Inc. CAH	$380M	-25%	Mar 2026
Henry Schein, Inc. HSIC	$112M	-0.9%	Mar 2026
Empro Group Inc. EMPG	$1M	—	Dec 2024
Akso Health Group AHG	$-1M	-250%	Mar 2026
Accendra Health, Inc. ACH	$-6M	-700%	Mar 2026
EDAP TMS S.A. FOCL	$-9M	-350%	Mar 2026

Full 20-quarter history · every available company

Net profit · reported quarter history

Accendra Health, Inc. · ACH

Jun 2021$66M

Sep 2021$44M

Dec 2021$42M

Mar 2022$39M

Jun 2022$29M

Sep 2022$12M

Dec 2022$-58M

Mar 2023$-24M

Jun 2023$-28M

Sep 2023$-6M

Dec 2023$20M

Mar 2024$-22M

Jun 2024$-7M

Sep 2024$1M

Dec 2024$-332M

Mar 2025$-4M

Jun 2025$-84M

Sep 2025$-6M

Dec 2025$-9M

Mar 2026$-6M

Akso Health Group · AHG

Jun 2021—

Sep 2021$-9M

Dec 2021—

Mar 2022$-8M

Jun 2022—

Sep 2022$2M

Dec 2022—

Mar 2023$-15M

Jun 2023—

Sep 2023$-3M

Dec 2023—

Mar 2024$-6M

Jun 2024—

Sep 2024$-1M

Dec 2024—

Mar 2025$27M

Jun 2025—

Sep 2025$-1M

Dec 2025—

Mar 2026—

Cardinal Health, Inc. · CAH

Jun 2021$115M

Sep 2021$272M

Dec 2021$49M

Mar 2022$-1.4B

Jun 2022$132M

Sep 2022$111M

Dec 2022$-130M

Mar 2023$347M

Jun 2023$-66M

Sep 2023$-11M

Dec 2023$369M

Mar 2024$262M

Jun 2024$233M

Sep 2024$417M

Dec 2024$401M

Mar 2025$508M

Jun 2025$243M

Sep 2025$454M

Dec 2025$471M

Mar 2026$380M

Cencora, Inc. · COR

Jun 2021$295M

Sep 2021$436M

Dec 2021$449M

Mar 2022$555M

Jun 2022$363M

Sep 2022$299M

Dec 2022$476M

Mar 2023$428M

Jun 2023$479M

Sep 2023$349M

Dec 2023$603M

Mar 2024$421M

Jun 2024$488M

Sep 2024$7M

Dec 2024$494M

Mar 2025$717M

Jun 2025$690M

Sep 2025$-333M

Dec 2025$566M

Mar 2026$1.6B

EDAP TMS S.A. · FOCL

Jun 2021$-1M

Sep 2021$-1M

Dec 2021$2M

Mar 2022$0M

Jun 2022$2M

Sep 2022$0M

Dec 2022$-6M

Mar 2023$-8M

Jun 2023$-5M

Sep 2023$-4M

Dec 2023$-6M

Mar 2024$-5M

Jun 2024$-7M

Sep 2024$-7M

Dec 2024$-2M

Mar 2025$-7M

Jun 2025$-7M

Sep 2025$-6M

Dec 2025$-10M

Mar 2026$-9M

Empro Group Inc. · EMPG

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023$0M

Sep 2023—

Dec 2023$0M

Mar 2024—

Jun 2024$0M

Sep 2024—

Dec 2024$1M

Mar 2025—

Jun 2025—

Sep 2025—

Dec 2025—

Mar 2026—

Henry Schein, Inc. · HSIC

Jun 2021$164M

Sep 2021$162M

Dec 2021$152M

Mar 2022$186M

Jun 2022$167M

Sep 2022$162M

Dec 2022$51M

Mar 2023—

Jun 2023$128M

Sep 2023$148M

Dec 2023$17M

Mar 2024$98M

Jun 2024$106M

Sep 2024$99M

Dec 2024$96M

Mar 2025$113M

Jun 2025$94M

Sep 2025$109M

Dec 2025$103M

Mar 2026$112M

McKesson Corporation · MCK

Jun 2021$536M

Sep 2021$310M

Dec 2021$39M

Mar 2022$407M

Jun 2022$807M

Sep 2022$973M

Dec 2022$1.1B

Mar 2023$826M

Jun 2023$997M

Sep 2023$703M

Dec 2023$630M

Mar 2024$830M

Jun 2024$960M

Sep 2024$287M

Dec 2024$928M

Mar 2025$1.3B

Jun 2025$831M

Sep 2025$1.2B

Dec 2025$1.3B

Mar 2026$1.9B

Profit growth · reported quarter history

Accendra Health, Inc. · ACH

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022-56%

Sep 2022-73%

Dec 2022-238%

Mar 2023-162%

Jun 2023-197%

Sep 2023-150%

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024-1,760%

Mar 2025—

Jun 2025—

Sep 2025-700%

Dec 2025—

Mar 2026—

Akso Health Group · AHG

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023-250%

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 2025—

Jun 2025—

Sep 2025—

Dec 2025—

Mar 2026—

Cardinal Health, Inc. · CAH

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 202215%

Sep 2022-59%

Dec 2022-365%

Mar 2023—

Jun 2023-150%

Sep 2023-110%

Dec 2023—

Mar 2024-25%

Jun 2024—

Sep 2024—

Dec 20248.7%

Mar 202594%

Jun 20254.3%

Sep 20258.9%

Dec 202517%

Mar 2026-25%

Cencora, Inc. · COR

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 202223%

Sep 2022-31%

Dec 20226.0%

Mar 2023-23%

Jun 202332%

Sep 202317%

Dec 202327%

Mar 2024-1.6%

Jun 20241.9%

Sep 2024-98%

Dec 2024-18%

Mar 202570%

Jun 202541%

Sep 2025-4,857%

Dec 202515%

Mar 2026127%

EDAP TMS S.A. · FOCL

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022-400%

Mar 2023—

Jun 2023-350%

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 2025—

Jun 2025—

Sep 2025—

Dec 2025—

Mar 2026—

Henry Schein, Inc. · HSIC

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 20221.8%

Sep 20220.0%

Dec 2022-66%

Mar 2023—

Jun 2023-23%

Sep 2023-8.6%

Dec 2023-67%

Mar 2024—

Jun 2024-17%

Sep 2024-33%

Dec 2024465%

Mar 202515%

Jun 2025-11%

Sep 202510%

Dec 20257.3%

Mar 2026-0.9%

McKesson Corporation · MCK

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 202251%

Sep 2022214%

Dec 20222,769%

Mar 2023103%

Jun 202324%

Sep 2023-28%

Dec 2023-44%

Mar 20240.5%

Jun 2024-3.7%

Sep 2024-59%

Dec 202447%

Mar 202557%

Jun 2025-13%

Sep 2025305%

Dec 202535%

Mar 202642%

08 · compare level, then change

Return On Capital Employed

Empro Group Inc. has the highest ROCE among the 8 Medical Distribution companies compared here, at 39.6%. McKesson Corporation is next at 14.9%. The same company also holds the highest ROCE change, at +53 percentage points. 8 of 8 companies report a comparable reading, the latest through Dec 2024.

What the numbers say: Empro Group Inc. leads ROCE at 39.6%, 24.7 percentage points above McKesson Corporation. Empro Group Inc. has the strongest latest improvement at +53 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.

LeaderEmpro Group Inc. · 39.6%

Gap165.8% versus #2 · McKesson Corporation

Persistence1/1 recent comparable periods

Coverage8/8 companies · 136 observations

Investor read: Empro Group Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.

ROCEhighest

1Empro Group Inc. EMPG · older report40%

2McKesson Corporation MCK15%

3Cencora, Inc. COR5.3%

4Cardinal Health, Inc. CAH3.6%

5Henry Schein, Inc. HSIC2.3%

ROCE changefastest improvers

1Empro Group Inc. EMPG · older report+53.0 pp

2McKesson Corporation MCK+3.8 pp

3Akso Health Group AHG+0.3 pp

4Accendra Health, Inc. ACH+0.2 pp

5Henry Schein, Inc. HSIC0.0 pp

Return on capital · company comparison

8/8 level · 8/8 change

All-company data · latest reported quarter

Company	ROCE	ROCE change	Reported
Empro Group Inc. EMPG	40%	+53.0 pp	Dec 2024
McKesson Corporation MCK	15%	+3.8 pp	Mar 2026
Cencora, Inc. COR	5.3%	−1.2 pp	Mar 2026
Cardinal Health, Inc. CAH	3.6%	−2.8 pp	Mar 2026
Henry Schein, Inc. HSIC	2.3%	0.0 pp	Mar 2026
Accendra Health, Inc. ACH	0.8%	+0.2 pp	Mar 2026
Akso Health Group AHG	-0.7%	+0.3 pp	Mar 2026
EDAP TMS S.A. FOCL	-19%	−7.2 pp	Mar 2026

Full 20-quarter history · every available company

ROCE · reported quarter history

Accendra Health, Inc. · ACH

Jun 2021—

Sep 20213.1%

Dec 20213.0%

Mar 20222.0%

Jun 20222.4%

Sep 20222.0%

Dec 2022-1.8%

Mar 20230.3%

Jun 20230.3%

Sep 20230.7%

Dec 20231.7%

Mar 20240.3%

Jun 20240.5%

Sep 20241.0%

Dec 2024-9.1%

Mar 20250.6%

Jun 2025-1.7%

Sep 20251.1%

Dec 20251.0%

Mar 20260.8%

Akso Health Group · AHG

Jun 2021-13%

Sep 2021-13%

Dec 2021-25%

Mar 2022-25%

Jun 2022-0.7%

Sep 2022-0.7%

Dec 2022-67%

Mar 2023-67%

Jun 2023-15%

Sep 2023-15%

Dec 2023-4.3%

Mar 2024-4.3%

Jun 2024-0.3%

Sep 2024-0.3%

Dec 2024-1.0%

Mar 2025-1.0%

Jun 2025-0.4%

Sep 2025-0.4%

Dec 2025-0.7%

Mar 2026-0.7%

Cardinal Health, Inc. · CAH

Jun 2021—

Sep 20212.4%

Dec 2021-5.4%

Mar 2022-0.6%

Jun 20220.2%

Sep 20221.0%

Dec 2022-0.9%

Mar 20234.7%

Jun 20231.4%

Sep 2023-0.3%

Dec 20235.2%

Mar 20243.6%

Jun 20244.2%

Sep 20246.7%

Dec 20245.5%

Mar 20256.4%

Jun 20253.6%

Sep 20255.7%

Dec 20255.3%

Mar 20263.6%

Cencora, Inc. · COR

Jun 2021—

Sep 20214.3%

Dec 20214.8%

Mar 20225.5%

Jun 20223.2%

Sep 20223.1%

Dec 20224.3%

Mar 20234.0%

Jun 20234.7%

Sep 20233.6%

Dec 20236.1%

Mar 20244.0%

Jun 20244.8%

Sep 20241.0%

Dec 20245.0%

Mar 20256.5%

Jun 20255.1%

Sep 20250.1%

Dec 20254.5%

Mar 20265.3%

EDAP TMS S.A. · FOCL

Jun 2021—

Sep 2021-4.1%

Dec 20211.0%

Mar 2022-0.2%

Jun 2022-0.7%

Sep 2022-2.8%

Dec 2022-2.2%

Mar 2023-9.7%

Jun 2023-6.5%

Sep 2023-7.7%

Dec 2023-4.9%

Mar 2024-7.1%

Jun 2024-9.8%

Sep 2024-10%

Dec 2024-6.4%

Mar 2025-11%

Jun 2025-14%

Sep 2025-13%

Dec 2025-13%

Mar 2026-19%

Empro Group Inc. · EMPG

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023-13%

Mar 2024—

Jun 2024-42%

Sep 2024—

Dec 202440%

Mar 2025—

Jun 2025—

Sep 2025—

Dec 2025—

Mar 2026—

Henry Schein, Inc. · HSIC

Jun 2021—

Sep 20213.7%

Dec 20213.4%

Mar 20224.1%

Jun 20223.6%

Sep 20223.4%

Dec 20221.1%

Mar 2023—

Jun 20232.8%

Sep 20233.1%

Dec 20230.5%

Mar 20242.1%

Jun 20242.2%

Sep 20242.0%

Dec 20242.0%

Mar 20252.3%

Jun 20251.9%

Sep 20252.1%

Dec 20252.1%

Mar 20262.3%

McKesson Corporation · MCK

Jun 2021—

Sep 20213.0%

Dec 20211.6%

Mar 20223.5%

Jun 20226.1%

Sep 20227.0%

Dec 20228.0%

Mar 20236.7%

Jun 20237.2%

Sep 20236.4%

Dec 20234.3%

Mar 20248.3%

Jun 20246.7%

Sep 20244.0%

Dec 20248.9%

Mar 202511%

Jun 20256.4%

Sep 20259.4%

Dec 202511%

Mar 202615%

ROCE change · reported quarter history

Accendra Health, Inc. · ACH

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022−1.1 pp

Dec 2022−4.8 pp

Mar 2023−1.7 pp

Jun 2023−2.1 pp

Sep 2023−1.3 pp

Dec 2023+3.5 pp

Mar 20240.0 pp

Jun 2024+0.2 pp

Sep 2024+0.3 pp

Dec 2024−10.8 pp

Mar 2025+0.3 pp

Jun 2025−2.2 pp

Sep 2025+0.1 pp

Dec 2025+10.1 pp

Mar 2026+0.2 pp

Akso Health Group · AHG

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022+12.0 pp

Sep 2022+12.0 pp

Dec 2022−41.2 pp

Mar 2023−41.2 pp

Jun 2023−14.5 pp

Sep 2023−14.5 pp

Dec 2023+62.2 pp

Mar 2024+62.2 pp

Jun 2024+14.9 pp

Sep 2024+14.9 pp

Dec 2024+3.3 pp

Mar 2025+3.3 pp

Jun 2025−0.1 pp

Sep 2025−0.1 pp

Dec 2025+0.3 pp

Mar 2026+0.3 pp

Cardinal Health, Inc. · CAH

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022−1.4 pp

Dec 2022+4.5 pp

Mar 2023+5.3 pp

Jun 2023+1.2 pp

Sep 2023−1.3 pp

Dec 2023+6.1 pp

Mar 2024−1.1 pp

Jun 2024+2.8 pp

Sep 2024+7.0 pp

Dec 2024+0.3 pp

Mar 2025+2.8 pp

Jun 2025−0.6 pp

Sep 2025−1.0 pp

Dec 2025−0.2 pp

Mar 2026−2.8 pp

Cencora, Inc. · COR

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022−1.2 pp

Dec 2022−0.5 pp

Mar 2023−1.5 pp

Jun 2023+1.5 pp

Sep 2023+0.5 pp

Dec 2023+1.8 pp

Mar 20240.0 pp

Jun 2024+0.1 pp

Sep 2024−2.6 pp

Dec 2024−1.1 pp

Mar 2025+2.5 pp

Jun 2025+0.3 pp

Sep 2025−0.9 pp

Dec 2025−0.5 pp

Mar 2026−1.2 pp

EDAP TMS S.A. · FOCL

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022+1.3 pp

Dec 2022−3.2 pp

Mar 2023−9.5 pp

Jun 2023−5.8 pp

Sep 2023−4.9 pp

Dec 2023−2.7 pp

Mar 2024+2.6 pp

Jun 2024−3.3 pp

Sep 2024−2.6 pp

Dec 2024−1.5 pp

Mar 2025−4.3 pp

Jun 2025−3.9 pp

Sep 2025−2.5 pp

Dec 2025−6.8 pp

Mar 2026−7.2 pp

Empro Group Inc. · EMPG

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024+53.0 pp

Mar 2025—

Jun 2025—

Sep 2025—

Dec 2025—

Mar 2026—

Henry Schein, Inc. · HSIC

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022−0.3 pp

Dec 2022−2.3 pp

Mar 2023—

Jun 2023−0.8 pp

Sep 2023−0.3 pp

Dec 2023−0.6 pp

Mar 2024—

Jun 2024−0.6 pp

Sep 2024−1.1 pp

Dec 2024+1.5 pp

Mar 2025+0.2 pp

Jun 2025−0.3 pp

Sep 2025+0.1 pp

Dec 2025+0.1 pp

Mar 20260.0 pp

McKesson Corporation · MCK

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022+4.0 pp

Dec 2022+6.4 pp

Mar 2023+3.2 pp

Jun 2023+1.1 pp

Sep 2023−0.6 pp

Dec 2023−3.7 pp

Mar 2024+1.6 pp

Jun 2024−0.5 pp

Sep 2024−2.4 pp

Dec 2024+4.6 pp

Mar 2025+2.8 pp

Jun 2025−0.3 pp

Sep 2025+5.4 pp

Dec 2025+2.4 pp

Mar 2026+3.8 pp

09 · compare level, then change

Valuation Against Growth & Quality

McKesson Corporation has the lowest PEG among the 8 Medical Distribution companies compared here, at 0.46×. Cencora, Inc. is next at 0.47×. Henry Schein, Inc. has the lowest P/E at 21.8×, so level and change sit with different companies. 4 of 8 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: McKesson Corporation has the lowest comparable PEG at 0.46×, 2.1% below Cencora, Inc.. Only 4 of 8 companies have earnings and growth steady enough for the ratio to mean anything, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.

LeaderMcKesson Corporation · 0.46×

Gap2.1% versus #2 · Cencora, Inc.

Persistence0/8 recent comparable periods

Coverage4/8 companies · 17 observations

Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.

PEGlowest PEG

1McKesson Corporation MCK0.5

2Cencora, Inc. COR0.5

3Cardinal Health, Inc. CAH1.0

4Henry Schein, Inc. HSIC3.2

P/Elowest P/E

1Henry Schein, Inc. HSIC21.8

2McKesson Corporation MCK22.5

3Cencora, Inc. COR24.1

4Cardinal Health, Inc. CAH32.3

5Accendra Health, Inc. ACH67.3

Valuation · company comparison

4/8 level · 6/8 change

All-company data · latest reported quarter

Company	PEG	P/E	Reported
Henry Schein, Inc. HSIC	3.2	21.8	Mar 2026
Cardinal Health, Inc. CAH	1.0	32.3	Mar 2026
Cencora, Inc. COR	0.5	24.1	Mar 2026
McKesson Corporation MCK	0.5	22.6	Mar 2026
EDAP TMS S.A. FOCL	—	75.0	Mar 2026
Accendra Health, Inc. ACH	—	67.3	Mar 2026

Full 20-quarter history · every available company

PEG · reported quarter history

Cardinal Health, Inc. · CAH

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 20241.5

Jun 2024—

Sep 2024—

Dec 2024—

Mar 2025—

Jun 2025—

Sep 20250.9

Dec 20251.0

Mar 2026—

Cencora, Inc. · COR

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 20231.7

Dec 20231.2

Mar 20241.1

Jun 20241.3

Sep 2024—

Dec 2024—

Mar 2025—

Jun 2025—

Sep 2025—

Dec 20252.2

Mar 20260.5

Henry Schein, Inc. · HSIC

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 20251.5

Jun 20251.6

Sep 20250.7

Dec 20253.2

Mar 2026—

McKesson Corporation · MCK

Jun 2021—

Sep 2021—

Dec 2021—

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 20251.7

Jun 20252.4

Sep 2025—

Dec 20250.4

Mar 20260.5

P/E · reported quarter history

Accendra Health, Inc. · ACH

Jun 2021—

Sep 20219.9

Dec 202114.8

Mar 202217.5

Jun 202215.6

Sep 202215.1

Dec 202267.3

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 2025—

Jun 2025—

Sep 2025—

Dec 2025—

Mar 2026—

Cardinal Health, Inc. · CAH

Jun 2021—

Sep 202112.8

Dec 202127.0

Mar 2022—

Jun 2022—

Sep 2022—

Dec 2022—

Mar 202343.4

Jun 202375.1

Sep 2023152.3

Dec 202339.2

Mar 202448.7

Jun 202428.5

Sep 202421.1

Dec 202422.0

Mar 202521.5

Jun 202526.1

Sep 202523.7

Dec 202529.6

Mar 202632.3

Cencora, Inc. · COR

Jun 2021—

Sep 202116.2

Dec 202117.2

Mar 202218.9

Jun 202216.2

Sep 202216.8

Dec 202220.1

Mar 202320.6

Jun 202323.4

Sep 202321.1

Dec 202321.2

Mar 202425.2

Jun 202423.2

Sep 202429.9

Dec 202432.0

Mar 202532.3

Jun 202530.9

Sep 202539.3

Dec 202540.6

Mar 202624.1

EDAP TMS S.A. · FOCL

Jun 2021—

Sep 2021159.5

Dec 2021299.5

Mar 2022362.5

Jun 202285.0

Sep 202275.0

Dec 2022—

Mar 2023—

Jun 2023—

Sep 2023—

Dec 2023—

Mar 2024—

Jun 2024—

Sep 2024—

Dec 2024—

Mar 2025—

Jun 2025—

Sep 2025—

Dec 2025—

Mar 2026—

Henry Schein, Inc. · HSIC

Jun 2021—

Sep 202117.7

Dec 202116.8

Mar 202219.1

Jun 202216.6

Sep 202214.3

Dec 202220.4

Mar 2023—

Jun 202323.1

Sep 202323.6

Dec 202324.0

Mar 202425.5

Jun 202423.7

Sep 202430.1

Dec 202422.5

Mar 202520.6

Jun 202523.0

Sep 202520.0

Dec 202523.3

Mar 202621.8

McKesson Corporation · MCK

Jun 2021—

Sep 2021—

Dec 202127.9

Mar 202242.3

Jun 202234.7

Sep 202224.1

Dec 202217.2

Mar 202314.2

Jun 202315.9

Sep 202317.2

Dec 202321.0

Mar 202424.0

Jun 202426.1

Sep 202425.6

Dec 202426.1

Mar 202526.2

Jun 202529.2

Sep 202524.0

Dec 202523.6

Mar 202622.6

10 · before the conclusion, check the blind spots

What can make this comparison misleading?

This Medical Distribution comparison names 5 specific ways its own evidence can mislead, all listed below. 1 of the 8 companies reports on an older date than the sector's freshest reporters, so its rank is marked stale. A high growth rate can still be a low-base artefact.

Keep these limits visible

A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
1 company has an older fundamental reporting date than the sector’s freshest reporters; its rank carries a stale marker.

11 · evidence and freshness

How was this comparison built?

This comparison is built from the reported filings of 8 Medical Distribution companies, normalized to a common $ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Mar 2026 and market data through 2026-08-04. A second data feed fills gaps only after identity and scale reconciliation, and missing observations are never interpolated.

FundamentalsThrough Mar 2026 · up to 20 quarters per company

Market dataThrough 2026-08-04 · weekly price and relative-strength history

Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.

Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.

12 · questions investors ask, short speakable answers

Medical Distribution company comparison FAQs

These 22 answers restate the Medical Distribution comparison above in question form. Every one is computed from the same 8 companies and the same reported filings as the rankings and charts, current through Mar 2026. Price and relative-strength answers run through 2026-08-04. Nothing here is estimated, and none of it is a recommendation.

Is the Medical Distribution sector outperforming S&P 500?

Which Medical Distribution company is largest by revenue?

McKesson Corporation leads with revenue of $403,430 million, based on 6 of 8 comparable companies through Mar 2026.

Which Medical Distribution company is growing fastest?

Cardinal Health, Inc. has the fastest current revenue growth at 12.8%, across 6 of 8 comparable companies.

Which Medical Distribution company has the strongest 4-Factor Sector Score?

McKesson Corporation ranks first at 71.4/100 with 85.3% evidence confidence. The score prioritizes research; it is not a buy recommendation.

Which Medical Distribution company has the lowest comparable PEG?

McKesson Corporation has the lowest comparable PEG at 0.46, among 4 of 8 companies whose earnings and growth are steady enough for the ratio to mean anything.

How much history does this Medical Distribution comparison include?

The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Mar 2026. Missing observations remain blank rather than being estimated.

How is the 4-Factor Sector Score calculated?

The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.

Which Medical Distribution company is the biggest?

McKesson Corporation is the largest, with trailing-twelve-month revenue of $403,430 million, ahead of Cencora, Inc. at $328,681 million. That covers 6 of 8 companies with comparable reporting through Mar 2026.

Which Medical Distribution company has the best profit margins?

Empro Group Inc. has the highest operating margin at 36.1%, from 7 of 8 comparable companies. Empro Group Inc. shows the biggest recent improvement, at +65.6 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.

Which Medical Distribution company makes the most profit?

McKesson Corporation earns the most, at $5,099 million of trailing-twelve-month net profit, from 6 of 8 comparable companies. Cencora, Inc. has the fastest profit growth at 49.6%, though growth off a small or recovering profit base overstates how much has actually changed.

Which Medical Distribution company earns the highest return on capital?

Empro Group Inc. leads on return on capital employed at 39.6%, across 8 of 8 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.

Which Medical Distribution stock is the cheapest?

On PEG — where a LOWER number is cheaper — McKesson Corporation screens cheapest at 0.46×. Only 4 of 8 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.

Is the Medical Distribution sector beating the market?

Medical Distribution has outperformed S&P 500 by 32.8% over the last 52 weeks and 6.5% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 3 of 7 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.

Which Medical Distribution stock has the strongest price momentum?

EDAP TMS S.A. has the strongest relative strength against S&P 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.

Which Medical Distribution company scores highest for research priority?

McKesson Corporation scores 71.4 out of 100 with 85.3% evidence confidence, from 28.7 points on growth and earnings, 16.2 on capital efficiency, 15.9 on valuation and 10.6 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.

How many Medical Distribution companies does this comparison cover, and over what period?

It compares 8 listed companies over up to 20 reported quarters of fundamentals, ending Mar 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.

What is the total market cap of the Medical Distribution sector?

The 8 Medical Distribution companies on this page carry $223,317 million of combined market value. McKesson Corporation is the largest at $97,225 million, about 44% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-04.

What is the Medical Distribution sector's P/E ratio?

The median price-to-earnings ratio across the 8 Medical Distribution companies on this page is 32.3×, measured on the 6 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 2026-08-04.

How is the Medical Distribution sector performing?

3 of the 7 covered Medical Distribution companies are beating S&P 500 on Mansfield relative strength. The sector itself is 32.8% ahead of S&P 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-04.

How many Medical Distribution stocks are listed in the US?

This comparison covers 8 listed Medical Distribution companies in the US, each above the size floor the site applies. The full ranked list is on this page, with reported fundamentals through Mar 2026. Membership is the full industry list — nothing is dropped for having thin data.

Why are some values on this page blank?

A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.

Is this investment advice?

No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.